Evaluation of drugs with specific organ toxicities in organ-specific cell lines

Toxicological Sciences

Volumn 126, Issue 1, 2012, Pages 114-127

  Lin, Zhiwu ^a   Will, Yvonne ^a  

^a PFIZER INC   (United States)

Author keywords

Cmax; Cytotoxicity; In vitro; Liver cardiac nephrotoxicity

Indexed keywords

AXITINIB; AZATHIOPRINE; CHLOROQUINE; CISAPRIDE; CLARITHROMYCIN; CLOZAPINE; CYANOCOBALAMIN; DEFEROXAMINE MESYLATE; DEXAMETHASONE; DIPHENHYDRAMINE; ERLOTINIB; FLOXURIDINE; FLUTAMIDE; KETOTIFEN; MERCAPTOPURINE; METHOTREXATE; MIBEFRADIL; NEFAZODONE; QUININE; RIBAVIRIN; TROGLITAZONE;

ARTICLE; CARDIOTOXICITY; CELL LINE; CELL STRAIN HEPG2; CELL VIABILITY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG SCREENING; HUMAN; IC 50; IN VIVO STUDY; KIDNEY PROXIMAL TUBULE; LIVER CELL CARCINOMA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

EID: 84857963032     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr339     Document Type: Article

References (45)

1. Allen, J., Jeffrey, P., Williams, R., and Ratcliffe, A. J. (2010). Approaches to assessing drug safety in the discovery phase. Drugs Future 35, 67-75.
2. Andersen, M. E., Al-Zoughool, M., Croteau, M., Westphal, M., and Krewski, D. (2010). The future of toxicity testing. J. Toxicol. Environ. Health Part B Crit. Rev. 13, 163-196.
3. Antzelevitch, C. (2007). Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 9(Suppl. 4), iv4-iv15.
4. Bass, A. S., Cartwright, M. E., Mahon, C., Morrison, R., Snyder, R., McNamara, P., Bradley, P., Zhou, Y. Y., and Hunter, J. (2009). Exploratory drug safety: A discovery strategy to reduce attrition in development. J. Pharmacol. Toxicol. Methods 60, 69-78.
5. Bauman, J. L., Bauernfeind, R. A., Hoff, J. V., Strasberg, B., Swiryn, S., and Rosen, K. M. (1984). Torsade de pointes due to quinidine: Observations in 31 patients. Am. Heart J. 107, 425-430.
6. Benbow, J. W., Aubrecht, J., Banker, M. J., Nettleton, D., and Aleo, M. D. (2010). Predicting safety toleration of pharmaceutical chemical leads: Cytotoxicity correlations to exploratory toxicity studies. Toxicol. Lett. 197, 175-182.
7. Berg, N., De Wever, B., Fuchs, H. W., Gaca, M., Krul, C., and Roggen, E. L. (2011). Toxicology in the 21st century-Working our way towards a visionary reality. Toxicol. In Vitro 25, 874-881.
8. DeSanty, K. P., and Amabile, C. M. (2007). Antidepressant-induced liver injury. Ann. Pharmacother. 41, 1201-1211.
9. Dykens, J. A., Marroquin, L. D., and Will, Y. (2007). Strategies to reduce latestage compound attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 7, 161-175.
10. Dykens, J. A., and Will, Y. (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12, 777-785.
11. El-Shitany, N. A., El-Haggar, S., and El-desoky, K. (2008). Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem. Toxicol. 46, 2422-2428.
12. Fermini, B., and Fossa, A. A. (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Compound Discov. 2, 439-447.
13. Frid, A. A., and Matthews, E. J. (2010). Prediction of compound-related cardiac adverse effects in humans-B: Use of QSAR programs for early detection of compound-induced cardiac toxicities. Regul. Toxicol. Pharmacol. 56, 276-289.
14. Fu, Z., Guo, J., Jing, L., Li, R., Zhang, T., and Peng, S. (2010). Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice. Toxicol. In Vitro 24, 1584-1591.
15. Greene, N., Aleo, M. D., Louise-May, S., Price, D. A., and Will, Y. (2010). Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. Bioorg. Med. Chem. Lett. 20, 5308-5312.
16. Huang, R., Southall, N., Cho, M. H., Xia, M., Inglese, J., and Austin, C. P. (2008). Characterization of diversity in toxicity mechanism using in vitro cytotoxicity assays in quantitative high throughput screening. Chem. Res. Toxicol. 21, 659-667.
17. Inoue, T., Tanaka, K., Mishima, M., and Watanabe, K. (2007). Predictive in vitro cardiotoxicity and hepatotoxicity screening system using neonatal rat heart cells and rat hepatocytes. Proceedings of 6th World Congress on Alternatives & Animal Use in the Life Sciences, 21-25 August 2007. AATEX 14, 457-462.
18. Kangas, L., Grönroos, M., and Nieminen, A. L. (1984). Bioluminescence of cellular ATP: A new method for evaluating cytotoxic agents in vitro. Med. Biol. 62, 338-343.
19. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499.
20. Koren, G. (1989). The nephrotoxic potential of drugs and chemicals. Pharmacological basis and clinical relevance. Med. Toxicol. Adverse Drug Exp. 4, 59-72.
21. Lee, W. M. (2003). Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485.
22. Li, Y., Li, X., Wong, Y. S., Chen, T., Zhang, H., Liu, C., and Zheng, W. (2011). The reversal of cisplatin-induced nephrotoxicity by selenium nanoparticles functionalized with 11-mercapto-1-undecanol by inhibition of ROS-mediated apoptosis. Biomaterials 32, 9068-9076.
23. Marchant, C. A., Fisk, L., Note, R. R., Pate, M. L., and Suárez, D. (2009). An expert system approach to the assessment of hepatotoxic potential. Chem. Biodivers. 6, 2107-2114.
24. McKim, J. M., Jr. (2010). Building a tiered approach to in vitro predictive toxicity screening: A focus on assays with in vivo relevance. Comb. Chem. High Throughput Screen. 13, 188-206.
25. Miret, S., De Grone, E. M., and Klaffke, W. (2006). Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2. J. Biomol. Screen. 11, 184-193.
26. Mueller, H., Kassack, M. U., and Wiese, M. (2004). Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J. Biomol. Screen. 9, 506-515.
27. Nadanaciva, S., Dillman, K., Gebhard, D. F., Shrikhande, A., and Will, Y. (2010). High-content screening for compounds that affect mtDNA-encoded protein levels in eukaryotic cells. J. Biomol. Screen. 15, 937-948.
28. Nagai, J. (2006). Molecular mechanisms underlying renal accumulation of aminoglycoside antibiotics and mechanism-based approach for developing nonnephrotoxic aminoglycoside therapy. Yakugaku Zasshi 126, 327-335.
29. O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006). High concordance of compound-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580-604.
30. O'Connell, T. M., and Watkins, P. B. (2010). The application of metabonomics to predict compound-induced liver injury. Clin. Pharmacol. Ther. 88, 394-399.
31. Petty, R. D., Sutherland, L. A., Hunter, E. M., and Cree, I. A. (1995). Comparison of MTT and ATP-based assays for the measurement of viable cell number. J. Biolumin. Chemilumin. 10, 29-34.
32. Saah, A. J., and Hoover, D. R. (1997). "Sensitivity" and "specificity" reconsidered: The meaning of these terms in analytical and diagnostic settings. Ann. Intern. Med. 126, 91-94.
33. Schoonen, W. G., Westerink, W. M., de Roos, J. A., and Débiton, E. (2005). Cytotoxic effects of 100 reference compounds on HepG2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol. In Vitro 19, 505-516.
34. Schuster, D., Laggner, C., and Langer, T. (2005). Why drugs fail-A study on side effects in new chemical entities. Curr. Pharm. Des. 11, 3545-3559.
35. Schutte, M., Fox, B., Baradez, M. O., Devonshire, A., Minguez, J., Bokhari, M., Przyborski, S., and Marshall, D. (2011). Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. Assay Drug Dev. Technol. 9, 475-486.
36. Stricker, B. H. C. (1992). Drug-Induced Hepatic Injury. Elsevier, Amsterdam, The Netherlands.
37. Sui, Y., and Wu, Z. (2007). Alternative statistical parameter for highthroughput screening assay quality assessment. J. Biomol. Screen. 12, 229-234.
38. Weiss, M. (2011). Functional characterization of drug uptake and metabolism in the heart. Expert Opin. Drug Metab. Toxicol. 7, 1295-1306.
39. Westerink, W. M., and Schoonen, W. G. (2007a). Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21, 1581-1591.
40. Westerink, W. M., and Schoonen, W. G. (2007b). Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21, 1592-1602.
41. Wu, C. F., Chuang, W. P., Li, A. H., and Hsiao, C. H. (2009). Cardiac magnetic resonance imaging in sunitinib malate-related cardiomyopathy: No late gadolinium enhancement. J. Chin. Med. Assoc. 72, 323-327.
42. Xia, M., Huang, R., Witt, K. L., Southall, N., Fostel, J., Cho, M. H., Jadhav, A., Smith, C. S., Inglese, J., Portier, C. J., et al. (2008). Compound cytotoxicity profiling using quantitative high-throughput screening. Environ. Health Perspect. 116, 284-291.
43. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-105.
44. Zhang, L., Mu, X., Fu, J., and Zhou, Z. (2007). In vitro cytotoxicity assay with selected chemicals using human cells to predict target-organ toxicity of liver and kidney. Toxicol. In Vitro 21, 734-740.
45. Zimmerman, H. (1999). Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Lippincott Williams & Wilkins, Philadelphia, PA.